Gout Animations

Nuon Therapeutics Announces Positive Topline Results From A Phase 2a Study In Hyperuricemia
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia...

Gout Drug Benefits Kidney Disease Patients
A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN)...

BioCryst Initiates A Phase 2 Study Of BCX4208 Alone And In Combination With Allopurinol In Patients With Gout
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208...

EnzymeRx Announces Strong Phase 1 Results For Pegsitacase
April 29, 2010. EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome...

Nuon Therapeutics Identifies Novel Use And Advances NU1618 Into Development For Chronic Hyperuricemia In Patients With Gout
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010...

COLCRYS(R) (Colchicine, USP) Shows Superior Safety With Comparable Efficacy Compared To High-Dose Colchicine In Treatment Of Early Acute Gout Flares
A newly-published clinical study demonstrates that Colcrys® (colchicine, USP), a low-dose oral colchicine, is just as effective as high-dose colchicine in reducing pain associated with early acute gout flare, but with a safety profile statistically indistinguishable from placebo. The study, "High vs...

Savient Announces KRYSTEXXA(TM) Resubmitted BLA Accepted For Review By The FDA
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of and accepted for review the March 15, 2010 resubmission of the Biologics License Application (BLA) for KRYSTEXXAâ„¢ (pegloticase), a treatment for chronic gout in patients refractory to conventional therapy...

Gout Risk Factors For Women: Obesity, Hypertension, Alcohol And Diuretic Use
Researchers from Boston University School of Medicine found that women with serum uric acid levels over 5 mg/dl had a significantly lower risk of developing gout than men...

Molecular Prosthesis Against Gout
Researchers from the ETH Zurich's Department of Biosystems Science and Engineering (D-BSSE) have devised a new method for preventing and permanently eradicating the cause of gout. It involves implanting a biological network that regulates the uric acid levels autonomously. As Paracelsus once stated, the dose makes the poison...

Dual-Energy CT Accurately Diagnoses Gout In Acute, Emergency Settings
A medical imaging technique called dual-energy computed tomography (CT) is an effective and reliable way to diagnose gout in the acute, emergency setting, according to a study published in the April issue of the American Journal of Roentgenology. Dual-energy CT is an advanced medical imaging technique that can detect vessels and bones and display them in clear contrast to one another...

Launch By Menarini And Ipsen Of ADENURIC(R) (febuxostat) In France For The Treatment Of Chronic Hyperuricemia In Gout
Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN), a global biotechnology specialty care group and Menarini, the first Italian pharmaceutical Group in the world with a significant pan-European presence, announced the launch of ADENURIC® (febuxostat) in France where they will co-promote the drug. Other launches by Menarini are planned shortly, notably in United Kingdom, Germany and Ireland...

Women With Gout At Greater Risk Of Heart Attack Than Men
Women with gout are at greater risk of a heart attack than men with the disease, indicates research published ahead of print in the Annals of the Rheumatic Diseases. Gout is known to boost the risk of a heart attack in men. But to date, little has been known about the impact of gout on women's cardiovascular health...

Ardea Biosciences Reports Positive Results For RDEA594, Its Lead Product Candidate For Gout, In Combination With Allopurinol Or Febuxostat
Ardea Biosciences, Inc...

Low-Dose Colchicine (Colcrys) Is Rapid, Effective Treatment For Acute Gout Flares
PHILADELPHIA - New data show that low-dose colchicine (ColcrysTM) rapidly controls acute gout flares. The results, which were presented at the 2009 Annual Scientific Meeting of the American College of Rheumatology, are drawn from a secondary analysis of the phase III Acute Gout Flare Receiving Colchicine Evaluation (AGREE) trial...

Ardea Biosciences Announces Additional Positive Results From A Phase 2a Study Of RDEA594 At The 2009 ACR/ARHP Annual Scientific Meeting
Ardea Biosciences, Inc. (Nasdaq: RDEA) announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout...